What is the recommended protocol for a technetium‑99m pyrophosphate (99mTc‑PYP) scan to evaluate suspected transthyretin cardiac amyloidosis?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: May 26, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Technetium-99m Pyrophosphate (99mTc-PYP) Scan Protocol for Transthyretin Cardiac Amyloidosis

Perform both planar and SPECT imaging at 1 hour post-injection using 10 mCi of 99mTc-PYP with 750K counts and a 256 matrix—this provides optimal diagnostic accuracy with the shortest study time and lowest radiation exposure. 1

Image Acquisition Protocol

Timing and Technical Parameters

  • Inject 10 mCi of 99mTc-PYP intravenously
  • Image at 1 hour post-injection (3-hour imaging is optional but not necessary for most cases) 1, 2, 3
  • Acquire both planar and SPECT images at the same time point 1
  • Use 750K counts (not 2000K—this reduces study time without compromising quality) 4
  • Use 256 matrix for processing (provides better resolution with less extracardiac activity) 4

Why 1 hour is sufficient: Multiple studies demonstrate that 1-hour imaging has 98% sensitivity and 96% specificity, with identical SPECT results compared to 3-hour imaging 2, 3, 5. The pattern of SPECT uptake is identical at 1 and 3 hours in all cases 3.

Interpretation Algorithm: Three-Step Approach

Step 1: Visual Confirmation on SPECT

First, evaluate SPECT images to confirm diffuse myocardial radiotracer uptake 1

  • Differentiate true myocardial uptake from:

    • Residual blood pool activity
    • Focal myocardial infarction (regional uptake)
    • Overlapping bone (rib fractures, sternal uptake)
  • If excess blood pool activity is present, repeat SPECT at 3 hours 1

  • If no myocardial uptake on SPECT, the scan is negative (Grade 0)—stop here 1

  • If diffuse myocardial uptake is confirmed, proceed to Step 2

Critical point: SPECT is essential and reduces equivocal results from 83% to 25% compared to planar imaging alone 6. There is 16% discordance between planar interpretation and SPECT findings 3.

Step 2: Semi-Quantitative Visual Grading (Heart-to-Rib Comparison)

Compare myocardial uptake to rib uptake on both planar and SPECT images 1:

Grade Description Interpretation
0 No myocardial uptake, normal bone uptake Negative
1 Myocardial uptake < rib uptake Equivocal
2 Myocardial uptake = rib uptake Positive for ATTR-CA*
3 Myocardial uptake > rib uptake with mild/absent rib uptake Positive for ATTR-CA*

**Must exclude monoclonal plasma cell dyscrasia (see below)

If Grade 2 or 3: Diagnosis is confirmed—you do NOT need to calculate H/CL ratio 1

Step 3: Heart-to-Contralateral Lung (H/CL) Ratio (Only for Equivocal Cases)

Calculate H/CL ratio ONLY when:

  • Visual grade is 1 (equivocal), OR
  • There is interpretive uncertainty between Grade 1 vs 2 1

How to calculate:

  • Draw circular ROI over the heart on anterior planar images
  • Avoid sternal overlap
  • Maximize heart coverage without including adjacent lung
  • Mirror the same-sized ROI over contralateral chest (above diaphragm)
  • Exclude right ventricle from contralateral ROI 1

Diagnostic thresholds:

  • H/CL ≥1.5 at 1 hour = positive for ATTR-CA 1
  • H/CL ≥1.3 at 3 hours = positive for ATTR-CA (if 3-hour imaging performed) 1

Critical caveat: H/CL ratio alone CANNOT diagnose ATTR-CA—myocardial uptake must be visually confirmed on SPECT first 1. Do not calculate H/CL if there is no myocardial uptake on SPECT 1.

Essential Exclusion Criteria

ALWAYS exclude AL (light-chain) amyloidosis before diagnosing ATTR-CA 1:

  • Order serum and urine immunofixation
  • Order serum free light chains assay
  • This is mandatory because >20% of AL cardiac amyloidosis patients can have Grade 2 or 3 uptake 1

Other causes of positive uptake to exclude:

  • Recent myocardial infarction (causes regional, not diffuse uptake) 1
  • Pericarditis 1
  • Chemotherapy-induced myocardial toxicity 1

Common Pitfalls and How to Avoid Them

Pitfall 1: Relying on Planar Imaging Alone

Solution: Always obtain SPECT imaging—it reduces equivocal results by 58-70% and has 16% discordance with planar interpretation 3, 6

Pitfall 2: Using Only H/CL Ratio Without Visual Confirmation

Solution: Never diagnose ATTR-CA based on H/CL ratio alone. SPECT visual confirmation is mandatory 1

Pitfall 3: False-Low H/CL in Prior MI Patients

Solution: In patients with prior large myocardial infarction, H/CL may be falsely low because tracer uptake is limited to non-infarcted zones. Use SPECT and non-planar displays to visualize regional uptake 1

Pitfall 4: Unnecessary 3-Hour Imaging

Solution: One-hour imaging is sufficient in most cases. Only repeat at 3 hours if there is excess blood pool activity on initial SPECT 1, 2, 3

Pitfall 5: Missing AL Amyloidosis

Solution: Always obtain serum/urine immunofixation and free light chains before finalizing ATTR-CA diagnosis 1

Reporting Requirements

Required elements in your report 1:

  1. Demographics: Patient name, age, sex, indication, date, prior imaging/biopsy results
  2. Methods: Radiotracer dose, injection time, scan timing, technique (planar and SPECT)
  3. Findings:
    • Image quality
    • Visual scan interpretation (required)
    • Semi-quantitative grade relative to ribs (required)
    • H/CL ratio (optional; recommended for positive scans)
  4. Conclusion: Categorize as:
    • Not suggestive (Grade 0)
    • Equivocal (Grade 1 or uncertainty between 1 vs 2)
    • Strongly suggestive (Grade 2 or 3 with diffuse uptake confirmed on SPECT)
  5. Statement: Document that AL amyloidosis exclusion with serum/urine immunofixation and free light chains is recommended

Why This Protocol Matters for Patient Outcomes

This standardized approach enables non-invasive diagnosis of ATTR-CA, potentially obviating endomyocardial biopsy 7. Early diagnosis is critical because novel disease-modifying therapies (tafamidis, patisiran, inotersen) can improve survival and quality of life when initiated before advanced heart failure develops 1. The 1-hour protocol provides 3 mSv radiation exposure versus 8-10 mSv with longer protocols, while maintaining diagnostic accuracy 4.

Related Questions

What is the appropriate next step in management for a patient with an equivocal technetium‑pyrophosphate (PYP) scan and otherwise negative laboratory and imaging workup?
What is the recommended initial management for a patient with transthyretin cardiac amyloidosis confirmed by a positive 99mTc‑pyrophosphate (PYP) scan?
What are the risks associated with a Technetium (TC-99m) pyrophosphate scan?
Does a heart to contralateral lung ratio of 1.1 indicate myocardial involvement in a patient with potential risk factors such as hypertension, chronic kidney disease, or a family history of amyloidosis?
What is the typical timeline for a patient to develop cardiac amyloidosis?
After excision of a basal cell carcinoma (basalioma) from the cheek, can I resume moderate exercise immediately?
What FDA‑approved medications are indicated for an adult with generalized anxiety disorder (GAD) who also has panic disorder and agoraphobia?
What is the optimal management for headaches caused by selective serotonin reuptake inhibitors (SSRIs)?
How should a 4‑month‑old infant weighing 4.5 kg with vomiting, high‑grade fever, and elevated serum glutamic‑pyruvic transaminase (SGPT) 130 U/L and serum glutamic‑oxaloacetic transaminase (SGOT) 60 U/L be managed?
Can a patient with an allergy to omeprazole (Prilosec) safely take pantoprazole (Protonix)?
Can a patient taking telmisartan and hydrochlorothiazide safely use a fixed‑dose combination tablet containing ibuprofen, paracetamol (acetaminophen), and caffeine for pain relief?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.